UPDATE: XOMA Receives Orphan Drug Designation From FDA for Gevokizumab
XOMA Corporation (Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that gevokizumab, the company's IL-1 beta modulating antibody, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.